ADVANCED SOLID TUMORS

This early-phase study tests a new cell therapy called GK01 in 15 adults with advanced solid tumors (like stomach or lung cancer) that have stopped responding to standard treatments. The main goals are to find the safest dose and check for side effects. Researchers will also meas…

This study tests a new drug, BPI-572270, in 120 adults with advanced solid tumors (like lung, colon, or pancreatic cancer) that have specific RAS gene mutations. The goal is to see if the drug is safe and can shrink tumors. Participants must have already tried standard treatments…

This study tests a new drug, SKB565, in about 180 adults aged 18-75 with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and can shrink tumors. The study has three parts: finding the right dose, expanding the dose, and …

This early-phase study tests an experimental therapy called WTX-212C, made from donor red blood cells that are engineered in a lab. It is given as an IV infusion to people with advanced solid tumors who have run out of standard options. The main goals are to check safety and find…

This study offers continued treatment with the drug RVU120 to people with advanced solid tumors, acute myeloid leukemia, or high-risk myelodysplastic syndrome who are already benefiting from it in an earlier study. Participants must have received at least 5 cycles of treatment an…

This early-phase study tests a combination of two drugs—peginterferon alfa-2b and an anti-PD-1 antibody—in about 60 people with advanced or metastatic solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and see if the combination …

This early-phase study tests a new drug called LCB02A in people with advanced solid tumors that have a specific protein (CLDN18.2) and have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors or slow their growth. About…

This early-stage study tests a new cell therapy called GK01 in 10 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check if the treatment is safe and to see how the body processes it. Researchers will also look for signs that t…

This early-phase study tests a new gene therapy injection called KXV01 TCR Lentinvivo in 30 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. Researchers will monitor side effects and look…

This study tests a new drug called QLS5132 combined with other cancer treatments for people with advanced solid tumors, including stomach, lung, endometrial, and ovarian cancers. The goal is to find safe doses and see if the combination can shrink tumors. About 626 participants w…

This early-phase study tests a new daily pill, KQB368, in adults with advanced solid tumors (like lung, colon, or uterine cancer) that have a KRAS G12S or G12C mutation and no standard cure. The main goals are to find a safe dose and see if the drug can shrink tumors. About 48 pa…

This early study tests a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to the patient. The main goals are to se…